Field Medical, Inc., a clinical-stage company specializing in next-generation pulsed field ablation (PFA) technology for cardiac treatment, has successfully closed a $35 million Series B financing round. This significant funding was co-led by BioStar Capital and Cue Growth, with continued participation from existing strategic investors. This latest infusion brings Field Medical's total funding to date to $75 million, reinforcing its position in PFA innovation for complex arrhythmias.

The primary objective of this Series B financing is to accelerate the initiation of the company's pivotal VERITAS trial. Additionally, the funds will support the further development of the FieldForce™ Ablation System and expand Field Medical's clinical and regulatory capabilities. This funding round was significantly influenced by strong pilot data showcased at the 2025 Heart Rhythm Society meeting, which helped attract institutional investor interest and solidified ongoing support from current investors.

The FieldForce™ Ablation System is a groundbreaking PFA technology engineered for transmural lesion creation, offering a novel approach to ventricular tachycardia (VT) ablation. Dr. Steven Mickelsen, founder and CEO of Field Medical and a pioneer in PFA technologies, highlighted that VT represents one of the most underpenetrated segments in electrophysiology, mirroring the early days of the AF (Atrial Fibrillation) market where strong clinical demand was unmet by existing tools. The FieldForce system is designed to unlock this opportunity, built for speed, precision, and tangible clinical progress for high-risk VT patients.

Louis Cannon, MD, founder and senior managing director of BioStar Capital, praised Field Medical's transformative technology for boldly addressing one of cardiology's most challenging and underserved areas with genuine innovation and urgency. Oskar Dadason, CFO of Field Medical, emphasized that this round reflects substantial momentum, driven not only by strong clinical results but also robust business fundamentals and confidence in their technology, strategy, and leadership.

In alignment with its accelerated growth trajectory, Field Medical has also announced updates to its Board of Directors. The board now includes Dr. Steven Mickelsen (Founder and CEO of Field Medical, inventor of PFA technologies like FARAPULSE™ and FieldForce™), Mark Wisniewski (CFO of Enterra Medical, now chairperson of the Field Medical board, bringing extensive medtech operational and M&A leadership), Marlou Janssen (experienced executive and board member, former President of Biotronik U.S. and VP/GM at EPD Solutions Philips, offering decades of commercial, product, and clinical strategy leadership in cardiology), Dr. Alexei Mlodinow (surgeon, serial entrepreneur, and investor with a strong track record in medtech innovation), and Ben Cannon (Founding Partner, Cue Growth, a seasoned venture capital investor providing institutional governance expertise).

Founded in 2022, Field Medical is dedicated to advancing PFA technologies for complex cardiac arrhythmias. Under the leadership of Dr. Steven Mickelsen, the FieldForce™ Ablation System integrates breakthrough catheter design with proprietary FieldBending™ energy to enable rapid, targeted ablation. In 2024, the company received Breakthrough Device Designation and was selected for the FDA TAP Pilot Program for its VT indication. It is important to note that the FieldForce™ Ablation System remains an investigational device, limited by federal law to investigational use.